<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01647880</url>
  </required_header>
  <id_info>
    <org_study_id>MOVING</org_study_id>
    <nct_id>NCT01647880</nct_id>
  </id_info>
  <brief_title>MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)</brief_title>
  <acronym>MOVING</acronym>
  <official_title>Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NeuroCure Clinical Research Center, Charite, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the MOVING study should be examined, whether early therapeutic intervention with
      fingolimod (Gilenya ®) after optic neuritis(ON) has a favorable visual outcome as a
      comparative therapie with Interferon beta-1b (Extavia®), as measured by multifocal visual
      evoked potentials (mVEP) after 6 month compared to baseline.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    delayed recruitment
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy parameters</measure>
    <description>Decrease of latency of mVEP of the affected eye after 6 months treatment with Gilenya® vs. Extavia® compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy parameters</measure>
    <description>Decrease in the latency of the mVEP from the affected eye at the time points 1, 3 and 12 months in comparison to baseline. Retinal nerve fiber layer thickness and macular volume in OCT, visual contrast sensitivity, visual field, Color vision, visual quality of life, in CMRT lesion load in cMRT , neurotrophic factors and axonal damage markers (neurofilament) and neurotrophins (for example, BDNF) in the serum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Fingolimod (Gilenya®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0,5 mg once a day in the morning, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon beta-1b (Extavia®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>every second day, s.c.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verum arm receiving Gilenya®</intervention_name>
    <arm_group_label>Fingolimod (Gilenya®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator receiving Extavia®</intervention_name>
    <arm_group_label>Interferon beta-1b (Extavia®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of relapsing-remitting multiple sclerosis (RRMS)

          -  ability to consent and a written approval

          -  First acute ON attack to the fit eye within 30 days before screening

          -  Age 18 - 55 years at screening

          -  EDSS ≤ 6.0

          -  No MS Attack except for ON in the last 30 days before screening

          -  No immunomodulatory therapy for at least three Months (before randomization), or

          -  strong immunomodulatory therapy with interferon beta or glatiramer acetate for at
             least 6 months

          -  visus in the affected eye at least 0.1

          -  latency of Conventional VEP in the affected eye

               -  = 115 ms or difference&gt; = 15 ms to the opposite side at a Study at least 4 but no
                  more than 6 weeks after Onset of clinical symptoms

          -  At least 2 T2 lesions typical of MS in a previous MRI

        Exclusion Criteria:

          -  other MS course than RRMS

          -  any condition which could interfere or prevent the MRI study or other investigations

          -  known allergy or intolerance, or other contraindication against Gd-DTPA

          -  Patients with known contraindications to treatment with fingolimod (Gilenya ®) or
             interferon beta-1b Extavia ®

          -  Competing diseases which could affect visual functions such as diabetic, retinopathy,
             glaucoma, retinal detachment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olaf Hoffmann, PD Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Charite- NeuroCure</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité-Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sankt Josefs Krankenhaus Potsdam Neurologie</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Friedemann Paul</investigator_full_name>
    <investigator_title>Sponsor Deputy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

